Drug
Atumelnant
Atumelnant: highest development phase Phase 3, developed by Crinetics Pharmaceuticals Inc.. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Crinetics Pharmaceuticals Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| Atumelnant NCT07144163 | Phase 3 | Congenital Adrenal Hyperplasia |
| Atumelnant NCT07159841 | Phase 2/3 | Congenital Adrenal Hyperplasia |
Latest
No recent events.
Follow Atumelnant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.